Puma Biotechnology (PBYI) Total Debt (2011 - 2026)

Puma Biotechnology's Total Debt history runs 11 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• Quarterly Total Debt fell 79.84% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 79.84% YoY) and the FY2025 annual result came in at $22.5 million, down 66.41% from the prior year.
• Total Debt was $11.3 million for Q1 2026 at Puma Biotechnology, down from $22.5 million in the prior quarter.
• Across five years, Total Debt topped out at $100.0 million in Q1 2024 and bottomed at $11.3 million in Q1 2026.
• A 5-year average of $75.9 million and a median of $97.4 million in 2022 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2024 — Total Debt gained 1.42% — and 2026, when it tumbled 79.84%.
• Puma Biotechnology's Total Debt stood at $98.3 million in 2022, then advanced by 1.37% to $99.7 million in 2023, then plunged by 32.72% to $67.0 million in 2024, then tumbled by 66.41% to $22.5 million in 2025, then sank by 49.9% to $11.3 million in 2026.
• Business Quant data shows PBYI's Total Debt at $11.3 million in Q1 2026, $22.5 million in Q4 2025, and $33.7 million in Q3 2025.